Oligometastatic disease has been proposed as an intermediate state between localised and
systemically metastasised disease. In the absence of randomised phase 3 trials, early …

Radiotherapy is an important modality used for the treatment of lung cancer. Seventy‐seven
percent of all patients with lung cancer have an evidence‐based indication for radiotherapy …

Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …

Background Recognizing the rapidly increasing interest and evidence in using metastasis-
directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO …

Importance Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1
(PD-1) and PD-1 ligand 1 have improved the outcome for many cancer types, the majority of …

Background Local treatment (metastasectomy or stereotactic radiotherapy) for
oligometastatic disease (OMD) in patients with esophagogastric cancer may improve overall …

Background Consensus about the definition and treatment of oligometastatic
oesophagogastric cancer is lacking. Objective To assess the definition and treatment of …

Background Local treatment improves the outcomes for oligometastatic disease (OMD, ie an
intermediate state between locoregional and widespread disseminated disease). However …

Oligometastatic (OMD) non‐small cell lung cancer (NSCLC) is a distinct but heterogeneous
entity. Current guidelines recommend systemic therapy and consolidation with local ablative …

Purpose Recent randomized studies have suggested improvements in progression-free and
overall survival with the addition of stereotactic body radiation therapy (SBRT, also known as …